Aquila Diagnostic Systems Inc.
Aquila Diagnostics Inc. is focused on the commercialization of a proprietary nucleic acid-based point-of-care rapid diagnostic tests for the detection of infectious pathogens and genetic markers. Our technology platform is a low cost, portable device with accompanying disposables that allows for low cost, accurate and timely detection of multiple targets in microliter volumes of biofluids at the point of care or need.
The founders of Aquila Diagnostics Systems Inc. have a vision that the convergence of developments in molecular diagnostics, microfluidic technology and portable electronics will create new opportunities to address the global challenges in the detection of infectious and pathogenic agents. Our corporate strategy has been to deploy leading practices in innovation management and product development that allow for the rapid design, engineering, and development of technology platforms that meet defined product and user specifications. Our goal at Aquila is to become a leading developer of diagnostic tests for disease.
Dr. Jason Acker, Aquila Founder and CTO, identified the need for a robust point of care diagnostic capability in 2007. Aquila Diagnostic Systems Inc. was formed in 2009. From 2011 to May 2015, Aquila went from laboratory proof of concept (2011) to alpha prototypes (2012) to three successful independent laboratory validations, one successful field evaluation, and initial instrument/chip sales (2013) to two additional successful field validations (2014) and two granted patents (2015). In 2016 Aquila developed a novel sample processing technology and filed its first submission for regulatory approval. Approximately $7 million has been invested into developing the technology during this period. In 2017, Aquila will initiate regulatory filings and develop new assays for the veterinary sector. In 2018 it plans to launch its first commercial product for the companion animal sector.